P152 Baseline characteristics and treatment effectiveness of abrocitinib in moderate-to-severe atopic dermatitis: results from the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR) cohort analysis

Abstract

Abrocitinib, a selective Janus kinase (JAK)1 inhibitor, is increasingly used for the treatment of moderate-to-severe atopic dermatitis (AD). However, real-world data on patient profiles and outcomes remain limited. The aim of this study was to describe the baseline demographics of adolescent and adult patients with moderate-to-severe AD on abrocitinib within the A-STAR cohort, and to analyse treatment effectiveness using endpoints of ≥ 50% and ≥ 75% improvement in Eczema Area and Severity Index (EASI 50 and EASI 75). A-STAR is a multicentre prospective observational register in the UK and Ireland evaluating the real-world effectiveness and safety of systemic treatments in AD. In total, 76 patients with moderate-to-severe AD from the registry who initiated abrocitinib were included in this analysis. Patient characteristics were summarized by age group, with continuous variables (e.g. age and body mass index) presented as mean (SD) and categorical variables as proportions. Treatment effectiveness was assessed by time to achieve EASI 50 and EASI 75 (as observed), requiring at least two EASI scores per treatment course. The mean age of the cohort was 33.3 years (SD 15.4); 80% were adults (61 of 76), 47% were female (36 of 76) and 75% were White (57 of 76). Common comorbidities included asthma (63%, 46 of 73), allergic rhinoconjunctivitis (45%, 34 of 76) and food allergies (47%, 35 of 74). The mean baseline EASI was 18.5 (SD 12.3); ranging from 23 (SD 13.8) in the adolescent cohort to 17.1 (SD 11.8) in the adult cohort. Previous therapies included biologics or JAK inhibitors (78%, 59 of 76), ciclosporin (61%, 46 of 76), methotrexate (68%, 52 of 76) and topical corticosteroids (88%, 67 of 76). Concomitant topical corticosteroids treatment was observed in 54% (41 of 76). The average time to EASI 50 was 3.67 months, and to EASI 75, 4.99 months. The probability of achieving EASI 50 increased from 8% at 1 month to 80% at 12 months, and EASI 75 from 4% to 65%. Within the context of the UK regular healthcare provision, patients with moderate-to-severe AD treated with abrocitinib in the A-STAR cohort showed diverse baseline characteristics and high rates of comorbid allergic conditions. Most achieved improvement in EASI scores within 5 months, supporting the effectiveness of abrocitinib in real-world practice.